Frankfurt - Delayed Quote EUR

Boiron SA (BON.F)

22.60
-0.05
(-0.22%)
At close: June 9 at 8:08:24 AM GMT+2

Key Executives

Amounts are as of December 31, 2024 and compensation values are for the last fiscal year ending on that date. Pay is salary, bonuses, etc. Exercised is the value of options exercised during the fiscal year. Currency in EUR.
NameTitlePayExercisedYear Born
Mr. Thierry Boiron Deputy GM & Director 455.31k -- 1961
Mr. Jean-Christophe Bayssat Deputy GM, Chief Pharmacist & Director of Pharmaceutical Development 655.35k -- 1963
Mr. Pascal Houdayer GM & Director -- -- 1969
Mr. Patrice Varraut Director of Operations -- -- --
Ms. Juliette Baudry Human Resources Director -- -- --
Mr. Fabrice Rey Group Treasurer -- -- --
Mr. Eric Lambert Secretary General -- -- --

Boiron SA

2, avenue de l’Ouest Lyonnais
Messimy, 69510
France
33 4 78 45 61 00 https://www.boiron.fr
Sector: 
Healthcare
Full Time Employees: 
2,469

Description

Boiron SA manufactures and sells homeopathic medicines in France, rest of Europe, North America, and internationally. The company offers non-proprietary homeopathic medicines and homeopathic specialties; and other healthcare products include medical devices, invitro diagnostics, dietary supplements, cosmetics, and phytotherapy. It also provides homeopathic specialties comprising Oscillococcinum to treat influenza symptoms, such as fever, chills, headaches, and aches; Stodal and Stodaline for treating coughs; Arnigel for adjunctive local treatment of benign trauma in the absence of open wounds; Camilia for the treatment of teething problems for babies; Sédatif PC to treat anxiety and emotional, and minor sleep disorders; Coryzalia for the treatment of cold symptoms and rhinitis; Homéoptic to treat eye discomfort and irritation due to various causes for adults and children; Homéovox for vocal disorders; Homéoplasmine for treating irritated skin and redness; Varésol to treat symptoms of chickenpox; and Arnicare Arthritis for use in the treatment of benign trauma pain. In addition, it offers Dermoplasmine, a plant based multi-use balm that repairs and protects irritated and damaged skin; COVID self-tests and rapid antigenic tests; LABIAMEO, that used to treat outbreaks of localized cold sores; and CONVAMEO to treat physical and mental asthenia. The company offers its products through distribution centers, pharmacies, pharmacy chains, wholesalers, grocery and drugstores, health food stores, and online retail. Boiron SA was founded in 1932 and is headquartered in Messimy, France.

Corporate Governance

Boiron SA’s ISS Governance QualityScore as of June 1, 2025 is 9. The pillar scores are Audit: 9; Board: 9; Shareholder Rights: 4; Compensation: 9.
Corporate governance scores courtesy of Institutional Shareholder Services (ISS) Scores indicate decile rank relative to index or region. A decile score of 1 indicates lower governance risk, while a 10 indicates higher governance risk.

Upcoming Events

April 3, 2025 at 10:59 AM UTC

Boiron SA Earnings Date

Recent Events

June 3, 2025 at 12:00 AM UTC

Ex-Dividend Date